Innocan Pharma's Groundbreaking Safety Study
Innocan Pharma Corporation (CSE: INNO, OTCQB: INNPF) has recently shared encouraging results from a comprehensive safety assessment study of its innovative drug, LPT-CBD. This exciting development marks a significant milestone for the pharmaceutical and biotechnology companies focused on enhancing patient care through cannabinoid technology.
Study Overview and Positive Outcomes
This study involved administering LPT-CBD through a single injection to Göttingen minipigs. The research methodology included three escalating doses, and the welfare of these animals was meticulously monitored for a total of 28 days. Key safety measures like clinical observations, vital sign checks, blood analysis, and local injection site reactions were rigorously assessed throughout the study.
Remarkable Safety Findings
Particularly noteworthy is the fact that no adverse events were recorded during the study period. The participating minipigs demonstrated a consistent normal weight gain, indicating their overall well-being. Moreover, LPT-CBD was well-tolerated; there were no reports of local reactions at the injection sites for any of the administered doses.
The Importance of Minipigs in Preclinical Research
Minipigs are recognized by the FDA as an invaluable model for translational research due to their significant anatomical and physiological similarities to humans. Their utility in pharmacokinetics studies, toxicity assessments, and evaluating drug efficacy makes them an essential aspect of developing new therapies. Innocan Pharma's choice to utilize minipigs ensures that their findings have real-world relevance and insight into how human systems may respond.
Expert Commentary on the Study
Prof. Chezy Barenholz, Innocan's Chief Scientific Officer, expressed his excitement regarding the study results. He emphasized that the promising safety profile of LPT-CBD in minipigs underscores its potential as a reliable toxicology model. Similarly, Dr. Eyal Kalo, the R&D Director, noted that these results strengthen the feasibility of LPT-CBD's forthcoming safety evaluations. This lays the groundwork for important upcoming regulatory milestones for the company.
About LPT-CBD
LPT-CBD represents a pioneering injectable liposomal formulation designed for the sustained release of cannabidiol (CBD). This innovative approach aims to address chronic pain management. Previous preclinical studies across various animal models have shown that LPT-CBD offers prolonged pharmacokinetics, translating into long-lasting therapeutic effects.
Innocan Pharma's Vision and Segments
Innocan operates primarily through two segments: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment puts substantial focus on advanced drug delivery technologies that incorporate cannabinoids, aiming to offer innovative treatments for diverse medical conditions. The company’s cutting-edge LPT CBD-loaded liposome platform is designed for precise dosing and controlled CBD release, targeting chronic pain management optimally.
Consumer Wellness Initiatives
Meanwhile, the Consumer Wellness segment is dedicated to creating and selling a range of effective self-care products aimed at promoting overall health and well-being. Innocan further enhances its reach through BI Sky Global Ltd., its subsidiary that specializes in advanced online sales strategies.
Contact Information for Innocan Pharma
For inquiries, reach out to:
Iris Bincovich, CEO
Tel: +1 516-210-4025
Tel: +972-54-301-2842
Tel: +44-20-3769-9377
Email: info@innocanpharma.com
Frequently Asked Questions
What is the purpose of Innocan Pharma's study?
The study focuses on the safety assessment of the LPT-CBD drug administered to minipigs, aimed at supporting its regulatory milestones.
How were the animals monitored during the study?
Animals were closely observed for clinical observations, vital signs, blood parameters, and any local injection site reactions throughout a 28-day period.
What results did Innocan Pharma report from the study?
The study reported no adverse events, normal weight gain in minipigs, and no localized reactions at the injection sites.
Why are minipigs used in this type of research?
Minipigs are recognized for their anatomical and physiological similarities to humans, making them suitable for preclinical studies to gain insights relevant for human health.
What does LPT-CBD aim to treat?
LPT-CBD is designed primarily for the sustained release of CBD, targeting chronic pain management to improve the quality of life for patients.
